Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 9, 2006, Pages 1696-1702

  Fortuny, Joan ^a   Kogevinas, Manolis ^a,c   Garcia Closas, Montserrat ^d   Real, Francisco X ^a   Tardón, Adonina ^e   Garcia Closas, Reina ^f   Serra, Consol ^b,g   Carrato, Alfredo ^h   Lloreta, Josep ^a   Rothman, Nat ^d   Villanueva, Cristina ^a   Dosemeci, Mustafa ^d   Malats, Núria ^a   Silverman, Debra ^d  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITY OF CRETE   (Greece)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF OVIEDO   (Spain)

^f HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^g Department of Pediatrics   (Spain)

^h Hospital General Universitari d'Elx   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; DIPYRONE; GLUTATHIONE TRANSFERASE P1; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL; PHENACETIN; PROPIONIC ACID; SALICYLIC ACID DERIVATIVE; SULFOTRANSFERASE;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG METABOLISM; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 33749357210     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0038     Document Type: Article

References (56)

1. Kogevinas M, Tricopoulos D. Urinary bladder cancer. In Adami HO, Hunter D, Tricopoulos D, editors. Textbook of cancer epidemiology. New York Oxford University Press; 2002. p. 446-66.
2. Silverman DT, Devessa SS, Moore LF, Rothman N. Bladder cancer. In: Schottenfeld D, Fraumeni J Jr, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2005.
3. McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF, Jr. A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst 1984;72:275-84.
4. McLaughlin JK, Gao YT, Gao RN, et al. Risk factors for renal-cell cancer in Shanghai, China. Int J Cancer 1992;52:562-5.
5. McCredie M, Stewart JH, Day NE. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 1993;53:245-9.
6. Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 1993;4:101-10.
7. McCredie M, Pommer W, McLaughlin JK. International renal-cell cancer study. II. Analgesics. Int J Cancer 1995;60:345-9.
8. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999;81:542-8.
9. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 1999;14:2892-7.
10. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Eng J Med 1985;313:292-5.
11. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000;82:1364-9.
12. McCredie M, Stewart JH. Does paracetamol cause urothelial cancer or renal papillary necrosis? Nephron 1988;49:296-300.
13. McCredie M, Stewart JH, Ford JM, MacLennan RA. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol 1983;55:220-4.
14. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime non-narcotic analgesic use and decline in renal function in women. Arch Intern Med 2004;164:1519-24.
15. Derby LE, Jick H. Acetaminophen and renal and bladder cancer. Epidemiology 1996;7:358-62.
16. Rosenberg L, Rao RS, Palmer JR, et al. Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control 1998;9:83-8.
17. Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, Blot WJ. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 2002;97:96-101.
18. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology 2001;12:690-4.
19. Steineck G, Wiholm BE, Gerhardsson de Verdier M. Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol 1995;34:741-8.
20. IARC. Non-steroidal anti-inflammatory drugs. 1997. IARC handbooks of cancer prevention. Lyon (France): IARC.
21. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacological and clinical issues. J Natl Cancer Inst 2002;94:252-66.
22. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
23. Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17:1435-8.
24. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID user: a population-based study. Br J Cancer 2003;88:1687-92.
25. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004;24:3177-84.
26. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic disease: a cohort study of the elderly. BMJ 1989;299:1247-50.
27. Sharpe CR, Franco EL. Use of dipyrone during pregnancy and risk of Wilms' tumour. Brazilian Wilms' Tumour Study Group. Epidemiology 1996;7:533-5.
28. Alexander FE, Patheal SL, Biondi A, et al. Transplacental chemical exposure and risk of infant leukaemia with MLL gene fusion. Cancer Res 2001;61:2542-6.
29. 1 mice. J Natl Cancer Inst 1983;71:1295-7.
30. Izumi K, Sano N, Otsuka H, Kinouchi T, Ohnishi Y. Tumour promoting potential in male F344 rats and mutagenicity in Salmonella typhimurium of dipyrone. Carcinogenesis 1991;12:1221-5.
31. Kari F, Bucher J, Haseman J, Eustis S, Huff J. Long-term exposure to the anti-inflammatory agent phenylbutazone induces kidney tumours in rats and liver tumours in mice. Jpn J Cancer Res 1995;86:252-63.
32. Uehara H, Otsuka H, Izumi K. Modifying effects of a mixture of acetaminophen, aspirin, dipyrone and ethenzamide on a multiorgan initiation model and its carcinogenicity in male F344 rats. Cancer Lett 1999;135:83-90.
33. De Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992;102:577-86.
34. Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 2002;65:135-50.
35. Kirchheiner J, Bröckmoller J. Clinical consequences of cytochrome P 450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16.
36. Geisslinger G, Bocker R, Levy M. High performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes. Pharm Res 1996;13:1272-5.
37. Spanish Pharmacists' Association. Catalago de Especialidades Farmacéuticas. Madrid: Spanish Pharmacists' Association; 2001.
38. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48.
39. Hu X, O'Donnell R, Srivastava SK, et al. Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7β,8α-dihydroxy-9α,10α-oxy-7,8,9,10-tetrahydrobenzo(a) pyrene. Biochem Biophys Res Commun 1997;18:424-8.
40. Persson I, Johansson I, Bergling H, et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993;319:207-11.
41. Montserrat Garcia-Closas, Núria Malats, Real FX, et al. Polymorphisms in N-acetyltransferase and glutathion transferase genes and risk of bladder cancer: Spanish Bladder Cancer Study and meta-analysis. Lancet 2005;366:649-59.
42. Villanueva CM, Cantor KP, Grimalt JO, et al. Assessment of lifetime exposure to trihalomethanes through different routes. Occup Environ Med 2006;63:273-7.
43. Langman MJS, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
44. Mohammed SI, Bennett PF, Craig BA, et al. Effects of cyclooxygenase inhibitor, piroxicam, on tumour response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-8.
45. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000;60:5599-602.
46. Shirahama T. Cyclooxygenase-2 expression is upregulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000;6:2424-30.
47. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505.
48. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
49. Hull MA, Gardner SH, Hawcroft G. Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treatment Reviews 2003;29:309-20.
50. Ramsay RG, Ciznadija D, Vanevski M, Mantmadiotis T. Transcriptional regulation of cyclooxygenase expression: three pillars of control. Int J Immunopathol Pharmacol 2003;2:59-67S.
51. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KW. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci 1999;96:5292-7.
52. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmöller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenase 1 and 2: no relation to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2002;55:51-61.
53. Pharmaceutical Drugs 50:307-332. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon (France): IARC; 1990.
54. García Rodríguez LA, González Pérez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004;91:525-9.
55. Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990;30:717-23.
56. Valderrama Gama E, Rodríguez Artalejo F, Palacios Díaz A, Gabarre Orús P, Pérez del Molino Martín J. The use of medications among the elderly: results of a population-based study. Rev Esp Salud Publica 1998;72:209-19.